ENSG
The Ensign Group, Inc.
ENSG's fundamentals are strong: revenue grew 17% and free cash flow grew 45%. At 28x earnings, it's trading in line with its usual 26x. Analysts expect earnings growth.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ENSG Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Strong |
ENSG's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ENSG PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 22x | $187 | — |
| Cheap | 23x | $153 | -18% |
| Fair | 25x | $171 | -8.2% |
| Current | 28x | $187 | — |
| Expensive | 32x | $216 | +16% |
Historical ranges are pointers, not guarantees.
ENSG's PE is in its expensive range at 28x. If earnings grow as analysts expect, today's price would be 22x next year's earnings, in its cheap range.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ENSG Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Stable | |
| Limited | |
| High |
ENSG has the edge over HIMS on the outlook, with more favorable earnings expectations.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ENSG Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $8.60 | +28% |
| Q3 2026 | $6.72 | +20% |
| Q2 2026 | $6.38 | +16% |
| Q1 2026 | $6.14 | +16% |
| Q4 2025 | $5.84 | +14% |
| Q3 2025 | $5.60 | +36% |
| Q2 2025 | $5.52 | +42% |
| Q1 2025 | $5.30 | +40% |
| Q4 2024 | $5.12 | +40% |
ENSG has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ENSG Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +14% |
| Q2 2026 | $1.4B | +17% |
| Q1 2026 | $1.4B | +18% |
| Q4 2025 | $1.4B | +20% |
| Q3 2025 | $1.3B | +20% |
| Q2 2025 | $1.2B | +18% |
| Q1 2025 | $1.2B | +16% |
| Q4 2024 | $1.1B | +15% |
ENSG's revenue has grown year over year every quarter since late 2020: $1.5B last quarter, up 14% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 9.3% | +1.9 points |
| Q2 2026 | 8.5% | 0 points |
| Q1 2026 | 9% | +0.3 points |
| Q4 2025 | 9.1% | +0.2 points |
| Q3 2025 | 7.4% | -0.8 points |
| Q2 2025 | 8.5% | +0.2 points |
| Q1 2025 | 8.6% | +0.5 points |
| Q4 2024 | 8.9% | +6.6 points |
ENSG has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over ENSG on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ENSG Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $240.2M | +57% |
| Q2 2026 | $172M | +10% |
| Q1 2026 | $100.2M | +39% |
| Q4 2025 | $183.3M | +82% |
| Q3 2025 | $153M | +14% |
| Q2 2025 | $155.7M | +102% |
| Q1 2025 | $72.2M | +105% |
| Q4 2024 | $100.5M | +18% |
ENSG has the edge over HIMS on cash flow, with more consistent year-over-year improvement.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS still generates free cash flow, though less than at its 2024 peak: $8M over the past year.
ENSG Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -180K shares |
| 1 year | +0.6% | +347K shares |
| 3 years | +3.4% | +2M shares |
| 5 years | +4.1% | +2.3M shares |
| Available history | +5.9% | +3.3M shares |
ENSG has 59M diluted shares, up 0.6% from a year ago.
| Quarter | Spent |
|---|---|
| Q3 2026 | $7.4M |
| Q2 2026 | $40M |
| Q1 2026 | — |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | $9.2M |
| Q1 2025 | $10.8M |
| Q4 2023 | — |
ENSG spent $47M buying back its own shares over the past year.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ENSG on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ENSG Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -0.2x | Net Cash |
| Q2 2026 | -0.2x | Net Cash |
| Q1 2026 | -0.7x | Net Cash |
| Q4 2025 | -0.7x | Net Cash |
| Q3 2025 | -0.6x | Net Cash |
| Q2 2025 | -0.5x | Net Cash |
| Q1 2025 | -0.3x | Net Cash |
| Q4 2024 | -0.7x | Net Cash |
ENSG has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ENSG Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 59.6 | Neutral |
| Stochastic | 70.3 | Neutral |
ENSG's weekly RSI is 60 (neutral) and its Stochastic is 70 (neutral).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ENSG PE vs Healthcare Sector
| Metric | ENSG | Sector median | Relative |
|---|---|---|---|
| PE | 28x | 26x | 7.4% above |
| PE % | 66 | 29 | 37 pts above |
ENSG is trading at 28x earnings, in line with the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ENSG Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $177.5 | 5.1% above |
| 20 week MA | $175.8 | 6.1% above |
| 50 week MA | $181.0 | 3.1% above |
| 100 week MA | $165.7 | 13% above |
| 200 week MA | $139.9 | 33% above |
ENSG has the edge over HIMS on trend strength, trading above more of its moving averages.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ENSG Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $44.7 | $72.8 | +63% |
| 2021 | $72.8 | $81.8 | +12% |
| 2022 | $81.8 | $95.0 | +16% |
| 2023 | $95.0 | $112.2 | +18% |
| 2024 | $112.2 | $134.0 | +19% |
| 2025 | $134.0 | $176.4 | +32% |
| 2026 YTD | $176.4 | $186.5 | +5.7% |
ENSG has the edge over HIMS on returns for 2026, with the stronger performance.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.